Phase 3 Clinical Trial Costs Exceed $26,000 per Patient

Oct 12, 2006, 01:00 ET from Cutting Edge Information

    RESEARCH TRIANGLE PARK, N.C., Oct. 12 /PRNewswire/ -- The cost per
 patient of running Phase 3 clinical studies of new pharmaceuticals exceeds
 $26,000, on average, according to a new benchmarking report, "Clinical
 Operations: Accelerating Trials, Allocating Resources and Measuring
 Performance" (http://www.ClinicalTrialBenchmarking.com), published by
 business intelligence firm Cutting Edge Information.
     The company surveyed dozens of leading pharmaceutical and biotech
 companies about their clinical development spending, staffing, and
 performance measurement practices. Survey data reveal that Phase 3 studies
 are the most costly as measured on a per-patient basis. Phase 2 trials are
 comparatively cheaper, with the average per-patient cost falling just over
 $19,300 per patient. Phase 1 trials, which test drugs' safety on a fraction
 of the number of patients tested in Phase 3 trials, are even less expensive
 at nearly $15,700 per patient.
     Cutting Edge Information developed "Clinical Operations: Accelerating
 Trials, Allocating Resources and Measuring Performance"
 (http://www.ClinicalTrialBenchmarking.com) using information gleaned from
 interviews and surveys with clinical trial operations and clinical
 development executives; trial managers; CRAs; and heads of medical writing,
 biostatistics, regulatory affairs, clinical quality assurance, and a host
 of other clinical trial support functions. The report also contains
 staffing metrics for more than 70 trials spanning the globe and covering
 nearly a dozen therapeutic areas and all phases of development.
     "We published 'Clinical Operations' to give our clients an
 off-the-shelf tool to help them benchmark the efficiency and performance of
 their individual trial teams and clinical development organizations as a
 whole," said Jon Hess, research team leader at Cutting Edge Information and
 lead author of the report. Hess says that "Clinical Operations"
 (http://www.ClinicalTrialBenchmarking.com) also contains lists of
 performance measures employed by the pharmaceutical, biotech and medical
 device companies profiled in the report, as well as target and actual
 performance metrics.
     Case studies, best practices and tactics for addressing key operational
 challenges are the foundation of the report's qualitative information. A
 dozen of the most common clinical trial workflow bottlenecks are examined,
 and interviewed executives' innovative solutions for addressing challenges,
 such as delays in clinical trial document writing and reviews, are
 presented in case study format.
     To view a summary of "Clinical Operations: Accelerating Trials,
 Allocating Resources and Measuring Performance," visit
 http://www.ClinicalTrialBenchmarking.com or contact Jon Hess at
 Jon_Hess@cuttingedgeinfo.com or 919-433-0211.
 
 

SOURCE Cutting Edge Information
    RESEARCH TRIANGLE PARK, N.C., Oct. 12 /PRNewswire/ -- The cost per
 patient of running Phase 3 clinical studies of new pharmaceuticals exceeds
 $26,000, on average, according to a new benchmarking report, "Clinical
 Operations: Accelerating Trials, Allocating Resources and Measuring
 Performance" (http://www.ClinicalTrialBenchmarking.com), published by
 business intelligence firm Cutting Edge Information.
     The company surveyed dozens of leading pharmaceutical and biotech
 companies about their clinical development spending, staffing, and
 performance measurement practices. Survey data reveal that Phase 3 studies
 are the most costly as measured on a per-patient basis. Phase 2 trials are
 comparatively cheaper, with the average per-patient cost falling just over
 $19,300 per patient. Phase 1 trials, which test drugs' safety on a fraction
 of the number of patients tested in Phase 3 trials, are even less expensive
 at nearly $15,700 per patient.
     Cutting Edge Information developed "Clinical Operations: Accelerating
 Trials, Allocating Resources and Measuring Performance"
 (http://www.ClinicalTrialBenchmarking.com) using information gleaned from
 interviews and surveys with clinical trial operations and clinical
 development executives; trial managers; CRAs; and heads of medical writing,
 biostatistics, regulatory affairs, clinical quality assurance, and a host
 of other clinical trial support functions. The report also contains
 staffing metrics for more than 70 trials spanning the globe and covering
 nearly a dozen therapeutic areas and all phases of development.
     "We published 'Clinical Operations' to give our clients an
 off-the-shelf tool to help them benchmark the efficiency and performance of
 their individual trial teams and clinical development organizations as a
 whole," said Jon Hess, research team leader at Cutting Edge Information and
 lead author of the report. Hess says that "Clinical Operations"
 (http://www.ClinicalTrialBenchmarking.com) also contains lists of
 performance measures employed by the pharmaceutical, biotech and medical
 device companies profiled in the report, as well as target and actual
 performance metrics.
     Case studies, best practices and tactics for addressing key operational
 challenges are the foundation of the report's qualitative information. A
 dozen of the most common clinical trial workflow bottlenecks are examined,
 and interviewed executives' innovative solutions for addressing challenges,
 such as delays in clinical trial document writing and reviews, are
 presented in case study format.
     To view a summary of "Clinical Operations: Accelerating Trials,
 Allocating Resources and Measuring Performance," visit
 http://www.ClinicalTrialBenchmarking.com or contact Jon Hess at
 Jon_Hess@cuttingedgeinfo.com or 919-433-0211.
 
 SOURCE Cutting Edge Information